Follow
Svetlana Cherlin
Svetlana Cherlin
Biostatistician, Newcastle University, UK
Verified email at newcastle.ac.uk
Title
Cited by
Cited by
Year
New substitution models for rooting phylogenetic trees
TA Williams, SE Heaps, S Cherlin, TMW Nye, RJ Boys, TM Embley
Philosophical Transactions of the Royal Society B: Biological Sciences 370 …, 2015
552015
Prediction of treatment response in rheumatoid arthritis patients using genome‐wide SNP data
S Cherlin, D Plant, JC Taylor, M Colombo, A Spiliopoulou, E Tzanis, ...
Genetic epidemiology 42 (8), 754-771, 2018
162018
The effect of nonreversibility on inferring rooted phylogenies
S Cherlin, SE Heaps, TMW Nye, RJ Boys, TA Williams, TM Embley
Molecular Biology and Evolution 35 (4), 984-1002, 2018
112018
A Genome-wide Association Study Identifies SERPINB10, CRLF3, STX7, LAMP3, IFNG-AS1, and KRT80 As Risk Loci Contributing to Cutaneous Leishmaniasis …
LC Castellucci, L Almeida, S Cherlin, M Fakiola, RW Francis, ...
Clinical Infectious Diseases 72 (10), e515-e525, 2021
92021
Using penalized regression to predict phenotype from SNP data
S Cherlin, RAJ Howey, HJ Cordell
BMC proceedings 12 (9), 223-228, 2018
92018
Investigation of genetically regulated gene expression and response to treatment in rheumatoid arthritis highlights an association between IL18RAP expression and treatment response
S Cherlin, MJ Lewis, D Plant, N Nair, K Goldmann, E Tzanis, MR Barnes, ...
Annals of the rheumatic diseases 79 (11), 1446-1452, 2020
42020
Multi-arm Trial of Inflammatory Signal Inhibitors (MATIS) for hospitalised patients with mild or moderate COVID-19 pneumonia: a structured summary of a study protocol for a …
N Vergis, R Phillips, V Cornelius, A Katsarou, T Youngstein, L Cook, ...
Trials 22 (1), 1-4, 2021
32021
Developing and testing high‐efficacy patient subgroups within a clinical trial using risk scores
S Cherlin, JMS Wason
Statistics in medicine 39 (24), 3285-3298, 2020
32020
Innovative trial approaches in immune-mediated inflammatory diseases: current use and future potential
MJ Grayling, T Bigirumurame, S Cherlin, L Ouma, H Zheng, JMS Wason
BMC rheumatology 5 (1), 1-15, 2021
22021
Generalizing rate heterogeneity across sites in statistical phylogenetics
SE Heaps, TMW Nye, RJ Boys, TA Williams, S Cherlin, TM Embley
Statistical Modelling 20 (4), 410-436, 2020
12020
Developing a predictive signature for two trial endpoints using the cross-validated risk scores method
S Cherlin, J Wason
arXiv preprint arXiv:2007.01680, 2020
12020
A genome-wide association study highlights a regulatory role for IFNG-AS1 contributing to cutaneous leishmaniasis in Brazil
LC Castellucci, L Almeida, S Cherlin, M Fakiola, E Carvalho, ...
bioRxiv, 2020
12020
Detecting responses to treatment with fenofibrate in pedigrees
S Cherlin, MH Wang, H Bickeböller, RM Cantor
BMC genetics 19 (1), 133-140, 2018
12018
Rooting major cellular radiations using statistical phylogenetics
S Cherlin
Newcastle University, 2016
12016
Multi-Arm Trial of Inflammatory Signal Inhibitors (MATIS) for Hospitalised Patients with Mild or Moderate COVID-19 Pneumonia: A Structured Summary of a Study Protocol for a …
A Charania, N Vergis, R Phillips, V Cornelius, A Katsarou, T Youngstein, ...
Blood 138, 4200, 2021
2021
Cross-validated risk scores adaptive enrichment (CADEN) design
S Cherlin, J Wason
arXiv preprint arXiv:2111.02299, 2021
2021
LETTER Open Access
N Vergis, R Phillips, V Cornelius, A Katsarou, T Youngstein, L Cook, ...
2021
Developing and testing high-efficacy patient subgroups within a clinical trial using polygenic risk scores
S Cherlin, J Wason
TRIALS 20, 2019
2019
Prediction of treatment response from genome-wide SNP data in rheumatoid arthritis patients
S Cherlin, HJ Cordell
GENETIC EPIDEMIOLOGY 42 (7), 692-692, 2018
2018
Predicting Treatment Response in Rheumatoid Arthritis Using SNP Data
S Cherlin, HJ Cordell
GENETIC EPIDEMIOLOGY 41 (7), 666-666, 2017
2017
The system can't perform the operation now. Try again later.
Articles 1–20